Committee debates H.32 language on MOUD, detainee definitions, reentry medication continuity and contractor roles

The Corrections & Institutions Committee spent the bulk of the meeting reviewing H.32, a bill draft addressing continuity of care and medication for opioid use disorder (MOUD) in correctional facilities, definitions for incarcerated populations and the role of contractors in post‑release continuity.

Members asked Department of Corrections (DOC) representatives and policy staff to return with technical testimony. Committee members emphasized several open issues in the draft: whether to define "detainee" separately from "inmate" and "offender," how to trigger discretionary language ("may provide the detainee"), whether department language should explicitly include "or its contractor" (committee members argued that WellPath, the contractor that handles facility-level clinical logistics, does that legwork in each facility), and whether caseworkers and health navigators should be employees or contractors. One member summarized the definitional concern: "When you say inmate in the statute, it pertains to everyone. When you say offender, it only pertains to those who are sentenced," and recommended repeating precise definitions in this bill to avoid confusion.

On clinical operations the committee discussed intake screening and timelines in the draft: members favored screening every person within 24 hours of intake for substance use and for MOUD need, with the department determining whether an individual is currently using medication in the course of MOUD. The committee debated whether short‑term detainees should automatically be provided reentry medication; several members urged criteria tied to length of stay and clinical severity rather than a blanket rule. One committee member said, "If they've been relying on medication while being detained, I think we have an obligation to provide them a transition of that prescription," while also noting cases where rapid court releases make continuity impractical.

Members also discussed medication types and pilot programs. The draft's language was broadened from naming specific drugs (for example, buprenorphine) to refer to "proposed medication" to allow future flexibility, which members said could encompass injectables in the future. Committee members noted operational tradeoffs for injectables (reduced diversion risk and some administrative benefits) and cost concerns; the department said it was exploring a pilot but had not recommended a policy change.

Contracting and responsibilities surfaced repeatedly. Members noted that the draft sometimes uses "the department" and at other times "or its contractor;" several members argued keeping "or its contractor" clarifies that in practice contractor staff (for example, WellPath clinicians and facility-based health navigators) perform most of the reentry coordination. The committee also asked DIVA (an agency referenced to prepare aggregate reentry reports) to confirm capacity to produce a report on previously incarcerated individuals' MOUD continuation after reentry.

Committee members directed staff to schedule technical testimony from DOC medical staff and facility clinicians, WellPath, DIVA, and outside clinical experts (several clinicians were named as potential witnesses, including a Dr. Lord who works with MAT systems). They also asked staff to identify training currently provided to DOC staff on MOUD and to return with criteria options (for example, length of stay thresholds) to determine when detainees should receive medication on release.

No formal vote was recorded; the committee treated this meeting as drafting and fact‑finding. Members repeatedly instructed staff to return with DOC and contractor testimony before the committee considers moving the bill forward.